These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 12189361)

  • 21. Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation.
    Aigner C; Jaksch P; Winkler G; Czebe K; Taghavi S; Marta G; Klepetko W
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):480-4. PubMed ID: 16091875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.
    Asberg A; Rollag H; Hartmann A
    Expert Opin Pharmacother; 2010 May; 11(7):1159-66. PubMed ID: 20367273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.
    Perrottet N; Decosterd LA; Meylan P; Pascual M; Biollaz J; Buclin T
    Clin Pharmacokinet; 2009; 48(6):399-418. PubMed ID: 19650679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.
    Freeman RB
    Expert Opin Pharmacother; 2004 Sep; 5(9):2007-16. PubMed ID: 15330737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of valganciclovir pharmacokinetics in lung transplant recipients.
    Kiser TH; Fish DN; Zamora MR
    J Heart Lung Transplant; 2012 Feb; 31(2):159-66. PubMed ID: 22305377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens.
    Tängdén T; Cojutti PG; Roberts JA; Pea F
    Clin Pharmacokinet; 2018 Nov; 57(11):1399-1405. PubMed ID: 29546589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients.
    Vezina HE; Brundage RC; Balfour HH
    Br J Clin Pharmacol; 2014 Aug; 78(2):343-52. PubMed ID: 24528138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract.
    Winston DJ; Baden LR; Gabriel DA; Emmanouilides C; Shaw LM; Lange WR; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):635-40. PubMed ID: 16737936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days.
    Welker H; Farhan M; Humar A; Washington C
    Transplantation; 2010 Dec; 90(12):1414-9. PubMed ID: 21076372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evaluation of pharmacokinetics and safety of valganciclovir oral suspension treatment in pediatric kidney graft recipients--preliminary report].
    Rubik J; Kozłowski K; Grenda R; Prokurat S
    Przegl Lek; 2006; 63 Suppl 3():184-6. PubMed ID: 16898525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation.
    Devyatko E; Zuckermann A; Ruzicka M; Bohdjalian A; Wieselthaler G; Rödler S; Wolner E; Grimm M
    J Heart Lung Transplant; 2004 Nov; 23(11):1277-82. PubMed ID: 15539126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
    van der Heiden PL; Kalpoe JS; Barge RM; Willemze R; Kroes AC; Schippers EF
    Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants.
    Weng FL; Patel AM; Wanchoo R; Brahmbhatt Y; Ribeiro K; Uknis ME; Mulgaonkar S; Mathis AS
    Transplantation; 2007 Feb; 83(3):290-6. PubMed ID: 17297403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and dosage individualization of ganciclovir and valganciclovir in an infant with nephrotic syndrome associated with cytomegalovirus infection.
    Zhang B; Fila M; Fakhoury M; Baudouin V; Deschênes G; Jacqz-Aigrain E; Zhao W
    J Antimicrob Chemother; 2014 Apr; 69(4):1150-1. PubMed ID: 24252753
    [No Abstract]   [Full Text] [Related]  

  • 35. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
    Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
    Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of antiviral agents for the treatment of cytomegalovirus infection.
    Baillie GM
    Am J Health Syst Pharm; 2005 Apr; 62(8 Suppl 1):S14-7. PubMed ID: 15821261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts.
    Reusser P
    Expert Opin Investig Drugs; 2001 Sep; 10(9):1745-53. PubMed ID: 11772283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation.
    Manuel O; Perrottet N; Pascual M
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):955-65. PubMed ID: 22029513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of oral valganciclovir and intravenous ganciclovir administered to prevent cytomegalovirus disease in an adult patient receiving small-intestine transplantation.
    Fortún Abete J; Martín-Dávila P; Moreno S; Quijano Y; de Vicente E; Pou L
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2782-3. PubMed ID: 15215150
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection.
    Stockmann C; Roberts JK; Knackstedt ED; Spigarelli MG; Sherwin CM
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):205-19. PubMed ID: 25428442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.